References
- Al-Janabi A, Warren RB. Update on risankizumab for the treatment of moderate to severe psoriasis. Expert Opin Biol Ther. Internet]. 2020;20(11):1245–1251. [cited 2021 Aug 17]. Available from: 03-04
- Rivera R, LLamas-Velasco M, Hospital M, et al. Efectividad y tolerabilidad a corto plazo (16 semanas) de Risankizumab en Psoriasis en vida real: estudio multicéntrico de 7 hospitales de la Comunidad de Madrid [Internet]. 6° Congr. psoriasis. Madrid;2021. Available from: https://congreso-psoriasis.aedv.es/data/uploaded/wysiwyg/files/Programa_Psoriasis2021_Def.pdf.
- de Oliveira MDFSP, de Ode O RB, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol [Internet]. 2015;90:09–20. Available from:
- Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol Internet]. 2015 cited 2021 Aug 17;136:116–124.e7. Available from: https://pubmed.ncbi.nlm.nih.gov/25769911/
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Informe de Posicionamiento Terapéutico de risankizumab (Skyrizi®) en psoriasis en placas. 2020;1–14. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT_7-2020-risankizumab-Skyrizi.pdf?x71164.
- Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis [Internet]. Cochrane Database Syst Rev; 2020 [cited 2021 Aug 18]. Available from: https://pubmed.ncbi.nlm.nih.gov/31917873/
- Ruiz-Villaverde R, Ruiz-Carrascosa JC, Galán-Gutierrez M, et al. Risankizumab: a pilot study of short-term effectiveness and safety in real clinical practice. Dermatol Ther [Internet]. 2021;34. Available from:
- Megna M, Fabbrocini G, Ruggiero A, et al. efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: preliminary data of a real-life 16-week retrospective study. Dermatol Ther [Internet]. 2020;33. Available from:
- Hansel K, Zangrilli A, Bianchi L, et al. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic [Internet]. J Eur Acad Dermatol Venereol John Wiley & Sons, Ltd; 2021:e169–e170. [cited 2021 Aug 19]. Available from:
- Reddy V, Yang EJ, Myers B, et al. Clinical evaluation of risankizumab-rzaa in the treatment of plaque psoriasis. J Inflamm Res [Internet]. 2020;13:53–60. Available from: https://www.dovepress.com/clinical-evaluation-of-risankizumab-rzaa-in-the-treatment-of-plaque-ps-peer-reviewed-article-JIR
- Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with Adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomized, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673619309523.
- Gordon KB, Strober B, Lebwohl M, et al. efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomized, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet [Internet]. 2018;392(10148):650–661. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618317136.
- Sugawara E, Nikaido H. Properties of AdeABC and AdeIJK efflux systems of Acinetobacter baumannii compared with those of the AcrAB-TolC system of Escherichia coli. Antimicrob Agents Chemother [Internet]. 2014;58(12):7250–7257. [cited 2021 Aug 19]. Available from: www.tcpdf.org
- Lebwohl M, et al. Poster 8108 [Internet]. American Academy of Dermatology (AAD) Annual Meeting; 2019 [cited 2021 Aug 19]. Available from: https://www.psoriasiscouncil.org/2019_aad_congress_report.htm#Systemic-therapies.